258 related articles for article (PubMed ID: 23811008)
1. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
2. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.
Zhang XY; Chen J; Zheng YF; Gao XL; Kang Y; Liu JC; Cheng MJ; Sun H; Xu CJ
Cancer Res; 2009 Aug; 69(16):6506-14. PubMed ID: 19638590
[TBL] [Abstract][Full Text] [Related]
3. Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.
Hong SS; Zhang MX; Zhang M; Yu Y; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):576-584. PubMed ID: 29461120
[TBL] [Abstract][Full Text] [Related]
4. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
5. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
6. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
7. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
9. [Preparation and in vitro targeting of follicle stimulating hormone polypeptide modified nanoparticles].
Zhang XY; Chen J; Gao XL; Sun H; Xu CJ
Zhonghua Fu Chan Ke Za Zhi; 2008 Jul; 43(7):533-7. PubMed ID: 19080519
[TBL] [Abstract][Full Text] [Related]
10. "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo.
Xiao K; Li Y; Lee JS; Gonik AM; Dong T; Fung G; Sanchez E; Xing L; Cheng HR; Luo J; Lam KS
Cancer Res; 2012 Apr; 72(8):2100-10. PubMed ID: 22396491
[TBL] [Abstract][Full Text] [Related]
11. Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy.
Fan L; Chen J; Zhang X; Liu Y; Xu C
Gynecol Oncol; 2014 Oct; 135(1):125-32. PubMed ID: 25003656
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
14. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma.
Gilmore D; Schulz M; Liu R; Zubris KA; Padera RF; Catalano PJ; Grinstaff MW; Colson YL
Ann Surg Oncol; 2013 May; 20(5):1684-93. PubMed ID: 23128939
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
Yao S; Li L; Su XT; Wang K; Lu ZJ; Yuan CZ; Feng JB; Yan S; Kong BH; Song K
J Exp Clin Cancer Res; 2018 Feb; 37(1):29. PubMed ID: 29478415
[TBL] [Abstract][Full Text] [Related]
18. Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues.
Kim JH; Bae SM; Na MH; Shin H; Yang YJ; Min KH; Choi KY; Kim K; Park RW; Kwon IC; Lee BH; Hoffman AS; Kim IS
J Control Release; 2012 Feb; 157(3):493-9. PubMed ID: 21945679
[TBL] [Abstract][Full Text] [Related]
19. Acid-sensitive nanoparticles filled with tumor-destroying drugs promise new method to target and kill ovarian cancer cells.
Nanomedicine (Lond); 2006 Oct; 1(3):261-6. PubMed ID: 17716157
[No Abstract] [Full Text] [Related]
20. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
